Charles Schwab Investment Management Inc. Raises Stock Position in Insulet Corporation $PODD

by · The Cerbat Gem

Charles Schwab Investment Management Inc. raised its position in Insulet Corporation (NASDAQ:PODD – Free Report) by 1.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 681,130 shares of the medical instruments supplier’s stock after purchasing an additional 6,763 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Insulet were worth $213,997,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Segall Bryant & Hamill LLC lifted its holdings in Insulet by 3.7% in the second quarter. Segall Bryant & Hamill LLC now owns 93,632 shares of the medical instruments supplier’s stock valued at $29,417,000 after acquiring an additional 3,300 shares during the last quarter. Stevens Capital Management LP acquired a new position in shares of Insulet in the 2nd quarter valued at $562,000. Rhumbline Advisers grew its holdings in shares of Insulet by 1.4% during the 2nd quarter. Rhumbline Advisers now owns 154,981 shares of the medical instruments supplier’s stock worth $48,692,000 after purchasing an additional 2,099 shares during the period. CenterBook Partners LP grew its holdings in shares of Insulet by 349.3% during the 2nd quarter. CenterBook Partners LP now owns 14,346 shares of the medical instruments supplier’s stock worth $4,507,000 after purchasing an additional 11,153 shares during the period. Finally, Mufg Securities Americas Inc. increased its position in shares of Insulet by 25.6% during the 2nd quarter. Mufg Securities Americas Inc. now owns 1,560 shares of the medical instruments supplier’s stock worth $490,000 after purchasing an additional 318 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have commented on PODD. Wells Fargo & Company upped their target price on shares of Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Wolfe Research upped their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Raymond James Financial boosted their target price on Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Zacks Research upgraded Insulet from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, Oppenheimer lifted their price objective on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $379.65.

Get Our Latest Report on Insulet

Insider Activity at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.39% of the company’s stock.

Insulet Trading Down 2.6%

PODD opened at $328.85 on Wednesday. The business has a fifty day moving average price of $322.10 and a 200 day moving average price of $316.13. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 12 month low of $230.05 and a 12 month high of $354.88. The stock has a market capitalization of $23.13 billion, a price-to-earnings ratio of 99.95, a PEG ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter last year, the business posted $1.08 EPS. The business’s quarterly revenue was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

See Also

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).